Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 267 500 KRW 0.38% Market Closed
Market Cap: 3.4T KRW
Have any thoughts about
Hanmi Pharm Co Ltd?
Write Note

Hanmi Pharm Co Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hanmi Pharm Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Pharm Co Ltd
KRX:128940
EPS (Diluted)
â‚©12.7k
CAGR 3-Years
27%
CAGR 5-Years
39%
CAGR 10-Years
17%
Yuhan Corp
KRX:000100
EPS (Diluted)
â‚©2.2k
CAGR 3-Years
11%
CAGR 5-Years
27%
CAGR 10-Years
4%
SK Biopharmaceuticals Co Ltd
KRX:326030
EPS (Diluted)
-â‚©419
CAGR 3-Years
50%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
EPS (Diluted)
â‚©1.6k
CAGR 3-Years
25%
CAGR 5-Years
44%
CAGR 10-Years
17%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
EPS (Diluted)
â‚©219
CAGR 3-Years
N/A
CAGR 5-Years
-17%
CAGR 10-Years
-7%
C
Celltrion Pharm Inc
KOSDAQ:068760
EPS (Diluted)
â‚©397
CAGR 3-Years
-27%
CAGR 5-Years
76%
CAGR 10-Years
10%
No Stocks Found

Hanmi Pharm Co Ltd
Glance View

Market Cap
3.4T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
375 064.4 KRW
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Hanmi Pharm Co Ltd's EPS (Diluted)?
EPS (Diluted)
12.7k KRW

Based on the financial report for Sep 30, 2024, Hanmi Pharm Co Ltd's EPS (Diluted) amounts to 12.7k KRW.

What is Hanmi Pharm Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
17%

Over the last year, the EPS (Diluted) growth was 22%. The average annual EPS (Diluted) growth rates for Hanmi Pharm Co Ltd have been 27% over the past three years , 39% over the past five years , and 17% over the past ten years .

Back to Top